The estimated Net Worth of Merrill A Mcpeak is at least $3.51 Million dollars as of 20 February 2024. Merrill Mcpeak owns over 250,000 units of Iovance Biotherapeutics Inc stock worth over $2,993,403 and over the last 10 years he sold IOVA stock worth over $0. In addition, he makes $515,363 as Independent Director at Iovance Biotherapeutics Inc.
Merrill has made over 16 trades of the Iovance Biotherapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 250,000 units of IOVA stock worth $2,287,500 on 20 February 2024.
The largest trade he's ever made was buying 250,000 units of Iovance Biotherapeutics Inc stock on 20 February 2024 worth over $2,287,500. On average, Merrill trades about 7,761 units every 47 days since 2015. As of 20 February 2024 he still owns at least 320,150 units of Iovance Biotherapeutics Inc stock.
You can see the complete history of Merrill Mcpeak stock trades at the bottom of the page.
Gen. (Retd.) Merrill A. McPeak serves as Independent Director of the Company. McPeak joined our Board of Directors in July 2011. From February 2015 until the appointment of Dr. Dukes as our new Chairman, General McPeak was the lead director on our Board of Directors. General McPeak also served as our unpaid, interim Chief Executive Officer from January 14, 2013 until July 24, 2013. General McPeak currently is the President of McPeak and Associates, a consulting firm that he founded in 1995. He has previously served as a director of several public companies, including Tektronix, Inc., Trans World Airlines, Inc., and ECC International Corp., where he was for many years the chairman of the board. General McPeak has served as a director of Research Solutions, Inc., a company engaged in developing systems to reuse published content, since November 2010, and of Aerojet Rocketdyne, an aerospace and defense contractor, since March 2013. He also served on the board of directors of Lilis Energy, an independent oil and gas producer, from January 2015 to April 2018. He was Chairman of the Board of Coast Plating, Inc., a privately held turnkey provider of metal processing and metal finishing services, from January 2009 until the company was acquired by Trive Capital and renamed Valence Surface Technologies, now the country’s largest independently owned aerospace and defense metal processing company. He continues to be a director of that company. He helped found, and from December 2003 to February 2012 was Chairman of the Board of EthicsPoint, Inc., a provider of risk management and compliance software-as-a-service that was acquired in 2012 and restyled Navex Global. General McPeak remained a member of the board of directors of Navex Global until that company was sold in 2014. From 1990 until his retirement from active military service in late 1994, General McPeak was Chief of Staff of the United States Air Force.
As the Independent Director of Iovance Biotherapeutics Inc, the total compensation of Merrill McPeak at Iovance Biotherapeutics Inc is $515,363. There are 8 executives at Iovance Biotherapeutics Inc getting paid more, with Maria Fardis having the highest compensation of $4,107,960.
Merrill McPeak is 84, he's been the Independent Director of Iovance Biotherapeutics Inc since 2011. There are no older and 15 younger executives at Iovance Biotherapeutics Inc.
Merrill's mailing address filed with the SEC is C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070.
Over the last 8 years, insiders at Iovance Biotherapeutics Inc have traded over $0 worth of Iovance Biotherapeutics Inc stock and bought 22,614,553 units worth $159,655,586 . The most active insiders traders include Wayne P. Rothbaum, Merrill A Mcpeak und Timothy E Morris. On average, Iovance Biotherapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $3,815,146. The most recent stock trade was executed by Frederick G Vogt on 3 September 2024, trading 57,292 units of IOVA stock currently worth $535,680.
iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical
Iovance Biotherapeutics Inc executives and other stock owners filed with the SEC include: